SEC filing record
Primary Source · SEC.gov

Avoro Life Sciences Offshore Fund Ltd.

Fund Vehicle2016 vintageRule 506(b), Section 3(c), Section 3(c)(7)Filing record

Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.

Latest signalSold increasedForm D/A · 2026-05-019 events: 3 sold increased, 3 investors increased, 3 large raiseLast filing 2026-05-01

Raised

$2.2B

Investors

290

Min Invest

$1,000,000

AltStreet Verified Issuer badge

Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.

What this filing shows

·

Every sentence is a value as filed on SEC Form D

Avoro Life Sciences Offshore Fund Ltd. is a Cayman Islands entity that first filed a Form D on October 17, 2014 and most recently amended it on May 1, 2026, describing itself as a hedge fund. The offering claims Rule 506(b), Section 3(c), Section 3(c)(7) and covers pooled investment fund interests. Avoro Life Sciences Offshore Fund Ltd. reported $2,180,159,075 sold from 290 investors in an offering of indefinite size as of the Form D filed May 1, 2026. The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. Because the fund also relies on Section 3(c)(7), each investor must be a qualified purchaser, generally an individual with at least $5 million in investments. The filing reports no non-accredited investors. The minimum investment accepted from an outside investor is $1,000,000. The Form D names Far Hills Group LLC (CRD 000032243), associated with None; Direct Access Partners, LLC (CRD 000120950), associated with None as recipients of sales compensation soliciting in all states. Sales commissions are reported as $63,681,725 and finders' fees as $0. Form D allows these to be estimates. The issuer's address of record is 110 Greene Street, Suite 800, New York, NY 10012.

EDGAR Filing Data

Form D — Primary Source

View on SEC.gov
CIK Number0001498990
Entity NameAvoro Life Sciences Offshore Fund Ltd.
ExemptionRule 506(b), Section 3(c), Section 3(c)(7)
What the exemption meansRule 506(b) of Regulation D: securities may be sold to an unlimited number of accredited investors and up to 35 non-accredited investors who meet the rule's sophistication standard, without general solicitation or advertising. Section 3(c) of the Investment Company Act of 1940: the issuer is a pooled investment vehicle relying on an exclusion from registration as an investment company. Section 3(c)(7) of the Investment Company Act: the fund is excluded from investment-company registration because every investor is a qualified purchaser, generally an individual with at least $5 million in investments or an institution with at least $25 million.
Entity TypeOther
Jurisdiction of OrganizationCayman Islands
Issuer Address110 Greene Street, Suite 800, New York, NY 10012
Phone(212) 937-4975
Former NamesvenBio Select Fund Ltd. (until September 7, 2018)
Industry / Fund TypePooled Investment Fund · Hedge Fund
Investment Company ActExcluded under Section 3(c)(7) (qualified purchasers only)
Securities TypePooled investment fund interests
First Sale DateJuly 1, 2010
Filing DateMay 1, 2026
Accession Number0000902664-26-002228
Total Offering AmountIndefinite
Total Amount Sold$2,180,159,075
Total Investors290
Non-Accredited InvestorsNone
Minimum Investment$1,000,000
Offering DurationIntended to last more than one year
Sales Commissions$63,681,725 (to Far Hills Group LLC and 1 other)
Finders' Fees$0
Net Asset Value RangeDecline to Disclose
State (Issuer Address)NY
Amendment Count13 filings on record

Filings on Record

Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.

In the Terminal

Filing events

9

latest May 1, 2026

Critical / warning

0 / 0

6 watch · 3 info

Statements extracted

0

none on file

NAV prints

0

none on file

Offering chains

1

raising

Latest event Sold increase · May 1, 2026

SEC.gov
Open in the terminal Watch this issuerInvestor $149/mo unlocks the values; Pro $349/mo adds the universe.

Fund family Part of the Avoro Life Sciences Fund family: 2 vehicles across 0 generations · adviser of record Avoro Capital Advisors LLC · full family and the filing behind each link in the terminal

Investor

  • The full fund family and any related vehicles (parallel, feeder, successor, sibling series) with the filing that shows each link
  • 9 filing events with values and deltas, latest 2026-05-01, and alerts on the next one
  • 1 offering timeline: velocity, share raised, first-sale lag, stalled flags

Pro

  • This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
  • The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV

Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…

Related Persons (Form D)

Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.

Avoro Capital Advisors LLC

Promoter · New York, NY

Investment Manager of the Issuer

Behzad Aghazadeh

Executive Officer · New York, NY

Portfolio Manager and Managing Partner of Avoro Capital Advisors LLC

Scott Epstein

Executive Officer · New York, NY

Partner, Chief Operating Officer & Chief Compliance Officer of Avoro Capital Advisors LLC

Neil Cammarosano

Executive Officer · New York, NY

Chief Financial Officer of Avoro Capital Advisors LLC

Avoro Capital GP, LLC

Promoter · New York, NY

General Partner of Avoro Capital L.P.

Avoro Capital L.P.

Promoter · New York, NY

Direct owner of Avoro Capital Advisors LLC

Placement Agents and Sales Compensation (Form D)

Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.

Far Hills Group LLCCRD 000032243 on BrokerCheck

Associated broker-dealer: None · NEW YORK, NY · Soliciting in all states

Direct Access Partners, LLCCRD 000120950 on BrokerCheck

Associated broker-dealer: None · NEW YORK, NY and outside the United States

Questions About Avoro Life Sciences Offshore Fund Ltd.

Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.

What is Avoro Life Sciences Offshore Fund Ltd.?

Avoro Life Sciences Offshore Fund Ltd. is a Cayman Islands entity that filed a Form D with the SEC on May 1, 2026 as a hedge fund. The filing claims Rule 506(b), Section 3(c), Section 3(c)(7) for an offering of pooled investment fund interests.

Is Avoro Life Sciences Offshore Fund Ltd. legit?

AltStreet does not rate legitimacy; it reports the public record. Avoro Life Sciences Offshore Fund Ltd. filed a Form D with the SEC on May 1, 2026 claiming Rule 506(b), Section 3(c), Section 3(c)(7). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $2,180,159,075 sold to 290 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.

Is Avoro Life Sciences Offshore Fund Ltd. registered with or approved by the SEC?

No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Avoro Life Sciences Offshore Fund Ltd. claimed Rule 506(b), Section 3(c), Section 3(c)(7) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.

How much has Avoro Life Sciences Offshore Fund Ltd. raised?

Avoro Life Sciences Offshore Fund Ltd. reported $2,180,159,075 sold from 290 investors in an offering of indefinite size as of the Form D filed May 1, 2026.

Who can invest in Avoro Life Sciences Offshore Fund Ltd.?

The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. Because the fund also relies on Section 3(c)(7), each investor must be a qualified purchaser, generally an individual with at least $5 million in investments. The filing reports no non-accredited investors. The minimum investment accepted from an outside investor is $1,000,000.

What is the minimum investment in Avoro Life Sciences Offshore Fund Ltd.?

The Form D lists $1,000,000 as the minimum investment accepted from any outside investor as of May 1, 2026. Issuers can waive their own minimums, and the figure does not include fees.

Who is selling Avoro Life Sciences Offshore Fund Ltd. and how are they paid?

The Form D names Far Hills Group LLC (CRD 000032243), associated with None; Direct Access Partners, LLC (CRD 000120950), associated with None as recipients of sales compensation soliciting in all states. Sales commissions are reported as $63,681,725 and finders' fees as $0. Form D allows these to be estimates.

Who is behind Avoro Life Sciences Offshore Fund Ltd.?

The Form D lists 6 related persons: Avoro Capital Advisors LLC, promoter (Investment Manager of the Issuer); Behzad Aghazadeh, executive officer (Portfolio Manager and Managing Partner of Avoro Capital Advisors LLC); Scott Epstein, executive officer (Partner, Chief Operating Officer & Chief Compliance Officer of Avoro Capital Advisors LLC); Neil Cammarosano, executive officer (Chief Financial Officer of Avoro Capital Advisors LLC); Avoro Capital GP, LLC, promoter (General Partner of Avoro Capital L.P); Avoro Capital L.P., promoter (Direct owner of Avoro Capital Advisors LLC). Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.

Where is Avoro Life Sciences Offshore Fund Ltd. located?

The issuer's address on its SEC filings is 110 Greene Street, Suite 800, New York, NY 10012. Its phone number of record is (212) 937-4975. It is organized under the laws of Cayman Islands.

How long is the Avoro Life Sciences Offshore Fund Ltd. offering open?

The issuer indicated that the offering is intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open; 13 amendments are on record for this CIK.

How large is Avoro Life Sciences Offshore Fund Ltd.?

The issuer declined to disclose its net asset value range on the Form D, which the form permits.

AltStreet Verified Issuer badge

Is this your company or fund?

Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.

Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.

Data Methodology

Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.